secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHEMED CORP (CHE)
CIK:        0000019584
Form:       8-K
Filed at:   2026-07-28T20:30:32+00:00
Accession:  0000019584-26-000018
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemed Q2 2026: adj. EPS $6.06 (+41.9%), VITAS EBITDA +20.6%, guidance raised to $25.00-$25.75
--------------------------------------------------------------------------------

- Consolidated revenue $673.3M (+8.8% YoY); GAAP diluted EPS $5.13 (+43.7%); adjusted diluted EPS $6.06 (+41.9%).
- VITAS net patient revenue $443.3M (+11.9%), ADC 23,687 (+6.1%), admissions +9.0%; adjusted EBITDA $80.6M (+20.6%).
- Roto-Rooter revenue $229.9M (+3.3%), adjusted EBITDA $48.5M (flat), margin 21.1% (-77 bps).
- Full-year 2026 adjusted EPS guidance raised to $25.00-$25.75 from $24.00-$24.75; mid-point +17.8% YoY.
- Repurchased 210,000 shares for $89.8M in Q2; trailing 12-month repurchases reduced shares by ~10.5%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/19584/000001958426000018/0000019584-26-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/19584/000001958426000018/che-20260728x8k.htm
  HTML page:      https://secwatch.observer/filing/0000019584-26-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer